← Leaderboards
Bertha K Madras
Harvard University (Medical School)
$13,356,360
Attributed
$13,356,360
Total exposure
66
Grants
25
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$13,356,360 · 66
By mechanism
R01$5,743,083 · 3
P51$4,322,975 · 59
R37$2,030,584 · 1
K05$581,255 · 1
R21$469,318 · 1
K02$209,145 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- Susan Valerie Westmoreland$3,881,883
- Gregory M Miller$6,444,253
Others in their field
Top investigators on “Dopamine Transporter”
- Pedro A. Jose · George Washington University$30,735,171
- Jonathan A Javitch · Columbia University Health Sciences$22,162,064
- Michael A Schwarzschild · Massachusetts General Hospital$19,646,494
- Aurelio Antonio Galli · University Of Alabama At Birmingham$14,357,586
- Diego A. Pizzagalli · Harvard University$11,403,501
- Haley E Melikian · Univ Of Massachusetts Med Sch Worcester$10,999,129
Research focus
Dopamine TransporterPharmacologyPrimatesCocaineNervous SystemSubstance Abuse Related DisorderMental DisordersAnimal TissueProteinsBrainDopamine ReceptorPharmaceutical PreparationsMacaca MulattaPositron Emission TomographyMammaliaHuman TissueAnalogGene ExpressionDrug Screening /EvaluationDopamineAnimal ColonyBehavioral /Social Science Research TagAddictionCorpus Striatum Structure
Grant awards (106)
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling$555,359
R01 · FY2021 · DA · contact PI
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling$561,653
R01 · FY2020 · DA · contact PI
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling$566,204
R01 · FY2019 · DA · contact PI
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling$570,509
R01 · FY2018 · DA · contact PI
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling$517,047
R01 · FY2017 · DA · contact PI
Methamphetamine and neurodevelopment in adolescent and adult mice$252,443
R21 · FY2011 · DA · contact PI
A PET STUDY OF DOPAMINERGIC ACTIVITY WITH ARMODAFINIL$13,753
P51 · FY2011 · RR · contact PI
DOPAMINE TRANSPORTER OCCUPANCY BY NOVEL PYROVALERONE ANALOGS, A PET STUDY$13,753
P51 · FY2011 · RR · contact PI
SYNTHESIS, BIOLOGICAL ASSESSMENT OF CANDIDATE MEDICATIONS FOR STIMULANT ABUSE$13,753
P51 · FY2011 · RR · contact PI
ADOLESCENT AND ADULT MICE RESPOND DIFFERENTLY TO METHAMPHETAMINE$13,753
P51 · FY2011 · RR · contact PI
MDMA ELICITS DIFFERENT BEHAVIORS, GENE EXPRESSION IN ADOLESCENT, ADULT MICE$13,753
P51 · FY2011 · RR · contact PI
Methamphetamine and neurodevelopment in adolescent and adult mice$216,875
R21 · FY2010 · DA · contact PI
DOPAMINE TRANSPORTER BINDING POTENTIAL INCREASES WITH AN ACUTE DOSE OF MDMA$18,052
P51 · FY2010 · RR · contact PI
PHENETHYLAMINE (PEA) AND ATTENTION DEFICIT HYPERACTIVITY DISORDER$18,052
P51 · FY2010 · RR · contact PI
PHENETHYLAMINE (PEA), THE DOPAMINE TRANSPORTER AND COCAINE$18,052
P51 · FY2010 · RR · contact PI
METHAMPHETAMINE MODULATES AXONAL GUIDANCE MOLECULES IN MOUSE HIPPOCAMPUS$18,052
P51 · FY2010 · RR · contact PI
Cocaine-Molecular Targets/Brain Imaging and Medications$116,251
K05 · FY2009 · DA · contact PI
ANTAGONISM OF MDMA-INDUCED IMPAIRMENT IN PRIMATES BY A NET INHIBITOR$34,958
P51 · FY2006 · RR · contact PI
REGULATION OF AXON GUIDANCE MOLECULE GENES: RELEVANCE TO BRAIN ADAPTATION$34,958
P51 · FY2006 · RR · contact PI
PYROVALERONE ANALOGS: A PROMISING CLASS OF MONOAMINE UPTAKE INHIBITORS$34,958
P51 · FY2006 · RR · contact PI
DOPAMINE TRANSPORT (DAT) INHIBITORS IMPROVE PARKINSONIAN DEFICITS$34,958
P51 · FY2006 · RR · contact PI
MDMA (?ECSTASY?) ANDTHE DOPAMINE TRANSPORTER$34,958
P51 · FY2006 · RR · contact PI
BRAIN DISTRIBUTION OF RHESUS MONKEY TRACE AMINE RECEPTORS TA1 AND TA4$34,958
P51 · FY2006 · RR · contact PI
THE TRACE AMINE PHENYLETHYLAMINE: ADHD AND COCAINE ABUSE$34,958
P51 · FY2006 · RR · contact PI
VARIANTS OF THE PRIMATE VESICULAR MONOAMINE TRANSPORTER-2$34,958
P51 · FY2006 · RR · contact PI
NOVEL MECHANISMS OF THE ANTI-NARCOLEPTIC DRUG MODAFINIL$34,958
P51 · FY2006 · RR · contact PI
REGULATION OF AXON GUIDANCE MOLECULE GENES: RELEVANCE TO BRAIN ADAPTATION$34,958
P51 · FY2006 · RR · contact PI
MDMA (ECSTASY) AND HUMAN MONOAMINE TRANSPORTERS: NEUROTOXICITY AND TREATMENT$34,958
P51 · FY2006 · RR · contact PI
PRIMATE TRACE AMINE RECEPTOR1 MODULATION BY THE DOPAMINE TRANSPORTER$34,958
P51 · FY2006 · RR · contact PI
COCAINE PHARMACOTHERAPIES: HETEROARYL ANALOGS OF 8-OXABICYCLOOCTANES$34,958
P51 · FY2006 · RR · contact PI
Evaluation of Novel Cocaine Medications$397,776
R01 · FY2005 · DA
Molecular Probes for Specific Cocaine Recognition Sites$380,250
R37 · FY2005 · DA
THE DEGYLCOSYLATED VMAT2 IS SMALLER THAN THE PREDICTED MOLECULAR SIZE$120,481
P51 · FY2005 · RR
MDMA, (?ECSTASY?) OCCUPIES THE DOPAMINE TRANSPORTER$120,481
P51 · FY2005 · RR
NEW ROLES FOR OLD TRACE AMINES AND MONOAMINE TRANSPORTERS$120,481
P51 · FY2005 · RR
NOREPINEPHRINE TRANSPORTER AND C-FOS PRODUCTION: RELEVANCE TO NEUROADAPTATION?$120,481
P51 · FY2005 · RR
ADHD MEDICATIONS AFFECT PERFORMANCE IN BEHAVIORAL TESTS$120,481
P51 · FY2005 · RR
DOPAMINE TRANSPORTER OCCUPANCY BY A ?TROPANE HORSE?: A COCAINE ANTAGONIST$120,481
P51 · FY2005 · RR
MOLECULAR TARGETS OF THE ANTI-NARCOLEPTIC DRUG MODAFINIL$120,481
P51 · FY2005 · RR
EPHS, IMPLICATED IN NEURODEVELOPMENT, ARE EXPRESSED IN ADULT PRIMATE BRAIN$120,481
P51 · FY2005 · RR
DIVERSE BRAIN TARGETS OF MDMA: BEYOND SEROTONIN AND ITS TRANSPORTER$120,481
P51 · FY2005 · RR
DOPAMINE TRANSPORTER MODULATION OF TRACE AMINE RECEPTOR1 SIGNALING$120,481
P51 · FY2005 · RR
THIA ANALOGS OF TROPANES: A NEW CLASS OF MONOAMINE TRANSPORT INHIBITORS$120,481
P51 · FY2005 · RR
REPETITIVE BEHAVIORS IN MONKEYS ARE LINKED TO STRIATAL ACTIVATION MAPS$120,481
P51 · FY2005 · RR
DURABILITY OF NEUROADAPTIVE RESPONSES TO COCAINE$120,481
P51 · FY2005 · RR
Cocaine-Molecular Targets/Brain Imaging and Medications$116,251
K05 · FY2005 · DA
Evaluation of Novel Cocaine Medications$386,191
R01 · FY2004 · DA
Molecular Probes for Specific Cocaine Recognition Sites$380,250
R37 · FY2004 · DA
Cocaine-Molecular Targets/Brain Imaging and Medications$116,251
K05 · FY2004 · DA
MOLECULAR TARGETS OF THE ANTI-NARCOLEPTIC DRUG MODAFINIL$14,843
P51 · FY2004 · RR
COCAINE-INDUCED BEHAVIORS IN SQUIRREL MONKEYS$14,843
P51 · FY2004 · RR
TROPANE ANALOGS OF DOPAMINE$14,843
P51 · FY2004 · RR
TECHNETIUM LABELED PROBE TO MONITOR DOPAMINE TRANSPORTER$14,843
P51 · FY2004 · RR
NON-AMINE DOPAMINE TRANSPORT INHIBITORS$14,843
P51 · FY2004 · RR
AN AMINE RECEPTOR (TAR1) IS A NOVEL AMPHETAMINE RECEPTOR$14,843
P51 · FY2004 · RR
MDMA SELECTIVE EFFECTS ON TRANSPORTERS /NEUROTOXICITY$14,843
P51 · FY2004 · RR
EPHRINS ARE EXPRESSED IN ADULT MONKEY BRAIN$14,843
P51 · FY2004 · RR
AN OPIOID RECEPTOR SNP: RELEVANCE TO STRESS RESPONSE$14,843
P51 · FY2004 · RR
TROJAN HORSE STRATEGY FOR DEVELOPING COCAINE ANTAGONISTS$14,843
P51 · FY2004 · RR
TRACE AMINE RECEPTOR: A NOVEL INDIRECT TARGET OF COCAINE$14,843
P51 · FY2004 · RR
A NEW CLASS OF MONOAMINE TRANSPORT INHIBITORS$14,843
P51 · FY2004 · RR
Molecular Probes for Specific Cocaine Recognition Sites$380,250
R37 · FY2003 · DA
Evaluation of Novel Cocaine Medications$374,943
R01 · FY2003 · DA
Cocaine-Molecular Targets/Brain Imaging and Medications$116,251
K05 · FY2003 · DA
MONOAMINE TRANSPORTER-DEPENDENT C-FOS INDUCTION: A NEUROADAPTIVE PROCESS?$14,224
P51 · FY2003 · RR
THE TROPANE HORSE: A NOVEL COCAINE ANTOGONIST STRATEGY$14,224
P51 · FY2003 · RR
PET IMAGING OF DOPAMINE TRANSPORTER DENSITY IN PARKINSON'S DISEASE$14,224
P51 · FY2003 · RR
MELATONIN PROMOTES SLEEP IN NONHUMAN PRIMATES$14,224
P51 · FY2003 · RR
THERAPEUTIC POTENTIAL OF DOPAMINE TRANSPORT INHIBITORS FOR PARKINSON'S DISEASE$14,224
P51 · FY2003 · RR
REPEATED COCAINE INDUCED NEURONAL RESPONSE CHANGES IN PRIMATE CAUDATE &PUTAMEN$14,224
P51 · FY2003 · RR
NONHUMAN PRIMATES AND HYPERACTIVITY DISORDERS$14,224
P51 · FY2003 · RR
NON-AMINE ANALOGS OF METHYLPHENIDATE (RITALIN)$14,224
P51 · FY2003 · RR
Evaluation of Novel Cocaine Medications$382,128
R01 · FY2002 · DA
MOLECULAR PROBES FOR SPECIFIC COCAINE RECOGNITION SITES$304,122
R37 · FY2002 · DA
Cocaine-Molecular Targets/Brain Imaging and Medications$116,251
K05 · FY2002 · DA
CLONING OF NON HUMAN PRIMATE DOPAMINE TRANSPORTERS$111,112
P51 · FY2002 · RR
SPECT IMAGING OF 5HT1A RECEPTOR$111,112
P51 · FY2002 · RR
MECHANISMS OF ANTI HYPERACTIVITY MEDICATIONS$111,112
P51 · FY2002 · RR
D2 DOPAMINE RECEPTOR AGONISTS POTENTIATE CANNABINOID INDUCED SEDATION$111,112
P51 · FY2002 · RR
ROLE OF AROMATIC AMINO ACID RESIDUES ON MONOAMINE TRANSPORTERS$111,112
P51 · FY2002 · RR
NON AMINES NEW GENERATION OF MONOAMINE REUPTAKE (DOPAMINE, SEROTONIN) INHIBITORS$111,112
P51 · FY2002 · RR
NON AMINES STRUCT ACTIVITY OF CARBATROPANES AT MONOAMINE TRANSPORTERS$111,112
P51 · FY2002 · RR
LABEL DOPAMINE NEURONS IN BRAINS OF NORMAL &MPTP TREATED MONKEYS$111,112
P51 · FY2002 · RR
NOVEL MARKERS AND DRUG THERAPIES FOR PARKINSON'S DISEASE$390,396
R01 · FY2001 · NS
EVALUATION OF NOVEL COCAINE MEDICATIONS$342,650
R01 · FY2001 · DA
MOLECULAR PROBES FOR SPECIFIC COCAINE RECOGNITION SITES$297,616
R37 · FY2001 · DA
D2 DOPAMINE RECEPTOR AGONISTS POTENTIATE CANNABINOID INDUCED SEDATION$111,112
P51 · FY2001 · RR
CLONING OF NON HUMAN PRIMATE DOPAMINE TRANSPORTERS$111,112
P51 · FY2001 · RR
ROLE OF AROMATIC AMINO ACID RESIDUES ON MONOAMINE TRANSPORTERS$111,112
P51 · FY2001 · RR
NON AMINES NEW GENERATION OF MONOAMINE REUPTAKE (DOPAMINE, SEROTONIN) INHIBITORS$111,112
P51 · FY2001 · RR
NON AMINES STRUCT ACTIVITY OF CARBATROPANES AT MONOAMINE TRANSPORTERS$111,112
P51 · FY2001 · RR
LABEL DOPAMINE NEURONS IN BRAINS OF NORMAL &MPTP TREATED MONKEYS$111,112
P51 · FY2001 · RR
SPECT IMAGING OF 5HT1A RECEPTOR$111,112
P51 · FY2001 · RR
MECHANISMS OF ANTI HYPERACTIVITY MEDICATIONS$111,112
P51 · FY2001 · RR
COCAINE--MOLECULAR TARGETS/BRAIN IMAGING AND MEDICATIONS$106,118
K02 · FY2001 · DA
NOVEL MARKERS AND DRUG THERAPIES FOR PARKINSON'S DISEASE$365,553
R01 · FY2000 · NS
EVALUATION OF NOVEL COCAINE MEDICATIONS$332,674
R01 · FY2000 · DA
MOLECULAR PROBES FOR SPECIFIC COCAINE RECOGNITION SITES$288,096
R37 · FY2000 · DA
COCAINE--MOLECULAR TARGETS/BRAIN IMAGING AND MEDICATIONS$103,027
K02 · FY2000 · DA
DEVELOPMENT OF GENE BANK OF RHESUS MONKEY BLOOD$13,085
P51 · FY2000 · RR
COCAINE MEDICATIONS &PET IMAGING$13,085
P51 · FY2000 · RR
COCAINE MEDICATIONS$13,085
P51 · FY2000 · RR
COCAINE ANTAGONISTS TROJAN HORSE CONCEPT$13,085
P51 · FY2000 · RR
NON AMINES DEVELOPMENT OF HIGHLY SELECTIVE DRUGS FOR DOPAMINE TRANSPORTER$13,085
P51 · FY2000 · RR
CANNABINOID &D2 LIKE DOPAMINE RECEPTOR AGONISTS &PROFOUND SEDATION IN PRIMATE$13,085
P51 · FY2000 · RR
ATTENTION DEFICIT HYPERACTIVITY ELEVATION OF DOPAMINE TRANSPORTER IN ADHD BRAIN$13,085
P51 · FY2000 · RR